Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354724 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
A Phase 1 study, sponsored by Denali Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07354724 is a Phase 1 study that is actively recruiting participants, run by Denali Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT07354724, a Phase 1 study, is actively recruiting participants, sponsored by Denali Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across varous dose levels of DNL952 in participants with late-onset Pompe disease (LOPD).
Interventions
- DRUG DNL952
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07354724
The ClinicalTrials.gov registry entry for NCT07354724 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DNL952 is the first listed.
NCT07354724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07354724 about?
NCT07354724 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease". This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across varous dose levels o...
What is the current status of trial NCT07354724?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-05-12. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07354724?
The interventions under investigation include: DNL952 (DRUG).
Who is sponsoring clinical trial NCT07354724?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.